IP Library Granted Patent US 12,552,797
Granted Patent B2
US 12,552,797 · App. 17/780,570 · Granted Feb 17, 2026

Process for making (3-[cyclopropylethoxy(difluoro)methyl]-6-6[5-fluoro-6-(2,2,2-trifluoroethoxy-3-pyridyl]- [1,2,4]triazolo[4,3-a]pyrazine

Inventors: Gabriel Martinez Botella (Wayland, MA); Andrew Mark Griffin (L'lle Bizard, CA)
Assignee: Praxis Precision Medicines, Inc.
C07D487/04A61K9/14A61P25/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,552,797
App. No.
17/780,570
Granted
Feb 17, 2026
Kind
B2
Abstract

The present invention is directed to, in part, a method of making (3-[cyclopropylethoxy(difluoro)methyl]-6-[5-fluoro-6-(2,2,2-trifluoroethoxy)-3-pyridyl]-[1,2,4]triazolo[4,3-α]pyrazine (Compound 1); comprising reacting key synthetic intermediates and providing methods of making the same.

Claims (19)

1 . A process for making Compound 1 of the following formula:

wherein the process comprises the following steps:

(i) contacting a solution of 2,2,2-trifluoroethanol with 5-bromo-2,3-difluoropyridine, thereby providing a compound of formula (II):

(ii) contacting the compound of formula (II) provided in step (i) above with a palladium catalyst and bis(pinacoloto)diboron, thereby providing a compound of formula (III):

(iii) contacting the compound of formula (III) provided in step (ii) above with a palladium catalyst and 2-bromo-5-chloropyrazine, thereby providing a compound of formula (IV):

(iv) contacting the compound of formula (IV) provided in step (iii) above with hydrazine, thereby providing a compound of formula (V):

(v) contacting the compound of formula (V) provided in step (iv) above with 2-bromo-2,2-difluoroacetyl chloride, thereby providing a compound of formula (VI):

(vi) contacting the compound of formula (VI) provided in step (v) above with an acid, thereby providing a compound of formula (VII):

and

(vii) contacting the compound of formula (VII) provided in step (vi) above with a silver catalyst and ethanol, thereby providing Compound 1 above.

2 . The process of claim 1 , wherein the silver catalyst in step (vii) is silver tetrafluoroborate.

3 . The process of claim 1 , wherein the acid in step (vi) is p-toluenesulfonic acid.

4 . The process of claim 1 , wherein the palladium catalyst in step (ii) is [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloride.

5 . The process of claim 1 , wherein the palladium catalyst in step (iii) is [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloride.

6 . The process of claim 1 , wherein:

(a) the palladium catalyst in step (ii) is [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloride;

(b) the palladium catalyst in step (iii) is [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloride;

(c) the acid in step (vi) is p-toluenesulfonic acid; and

(d) the silver catalyst in step (vii) is silver tetrafluoroborate.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 27, 2022
From: MARTINEZ BOTELLA, GABRIEL; LUNSMANN, WALTER J.; GARAD, SAPNA MAKHIJA; REED, DAVID; GRIFFIN, ANDREW MARK; KAHLIG, MICHAEL KRISTOPHER MATHIEU; MARRON, BRIAN EDWARD; LOYA, CARLOS
To: PRAXIS PRECISION MEDICINES, INC.
Reel/Frame 060035/0377 →
Continuity (8)
Provisional Application 62941322 · Nov 27, 2019
Provisional Application 62941319 · Nov 27, 2019
Provisional Application 63001801 · Mar 30, 2020
Provisional Application 63001906 · Mar 30, 2020
Provisional Application 63028229 · May 21, 2020
Provisional Application 63082857 · Sep 24, 2020
Provisional Application 63082864 · Sep 24, 2020
Related Publication 20230348466A1 · Nov 2, 2023
References Cited (214)
US 3845770A · Theeuwes et al. · 1974 [cited by applicant]
US 4112095A · Allen, Jr. et al. · 1978 [cited by applicant]
US 4230705A · Allen, Jr. et al. · 1980 [cited by applicant]
US 4242515A · Trust et al. · 1980 [cited by applicant]
US 4326525A · Swanson et al. · 1982 [cited by applicant]
US 4902514A · Barclay et al. · 1990 [cited by applicant]
US 4992445A · Lawter et al. · 1991 [cited by applicant]
US 5001139A · Lawter et al. · 1991 [cited by applicant]
US 5023252A · Hsieh et al. · 1991 [cited by applicant]
US 5616345A · Geoghegan et al. · 1997 [cited by applicant]
US 5905079A · Sargent et al. · 1999 [cited by applicant]
US 6589952B2 · Bakthavatchalam et al. · 2003 [cited by applicant]
US 7863279B2 · Even et al. · 2011 [cited by applicant]
US 8030305B2 · Lu et al. · 2011 [cited by applicant]
US 8173654B2 · Lu et al. · 2012 [cited by applicant]
US 8198448B2 · Albrecht et al. · 2012 [cited by applicant]
US 8212041B2 · Albrecht et al. · 2012 [cited by applicant]
US 8217177B2 · Albrecht et al. · 2012 [cited by applicant]
US 8524900B2 · Albrecht et al. · 2013 [cited by applicant]
US 8937060B2 · Cid-Nunez et al. · 2015 [cited by applicant]
US 8952034B2 · Corkey et al. · 2015 [cited by applicant]
US 9066954B2 · Albrecht et al. · 2015 [cited by applicant]
US 9371329B2 · Corkey et al. · 2016 [cited by applicant]
US 10280184B2 · Friedman et al. · 2019 [cited by applicant]
US 11014931B2 · Griffin et al. · 2021 [cited by applicant]
US 11261188B2 · Reddy et al. · 2022 [cited by applicant]
US 11278535B2 · Reddy et al. · 2022 [cited by applicant]
US 11279700B2 · Griffin et al. · 2022 [cited by applicant]
US 20020049208A1 · Bakthavatchalam et al. · 2002 [cited by applicant]
US 20080200536A1 · Moon et al. · 2008 [cited by applicant]
US 20090124609A1 · Albrecht et al. · 2009 [cited by applicant]
US 20090203707A1 · Rajamani et al. · 2009 [cited by applicant]
US 20100088778A1 · Mulley et al. · 2010 [cited by applicant]
US 20110021521A1 · Corkey et al. · 2011 [cited by applicant]
US 20120010192A1 · Kobayashi et al. · 2012 [cited by applicant]
US 20120065191A1 · Kiss et al. · 2012 [cited by applicant]
US 20120245164A1 · Auger et al. · 2012 [cited by applicant]
US 20120245165A1 · Auger et al. · 2012 [cited by applicant]
US 20130315895A1 · Farrell et al. · 2013 [cited by applicant]
US 20140066443A1 · Beshore et al. · 2014 [cited by applicant]
US 20140303158A1 · Corkey et al. · 2014 [cited by applicant]
US 20150038503A1 · Bourotte et al. · 2015 [cited by applicant]
US 20150284389A1 · Pero et al. · 2015 [cited by applicant]
US 20150344457A1 · Duncan et al. · 2015 [cited by applicant]
US 20160159801A1 · Quinn et al. · 2016 [cited by applicant]
US 20160235718A1 · Baraban · 2016 [cited by applicant]
US 20160297799A1 · Brookings et al. · 2016 [cited by applicant]
US 20160317536A1 · Reich et al. · 2016 [cited by applicant]
US 20190308938A1 · McCormack et al. · 2019 [cited by applicant]
US 20190389868A1 · Reddy et al. · 2019 [cited by applicant]
US 20200179358A1 · Reddy et al. · 2020 [cited by applicant]
US 20200247793A1 · Reddy et al. · 2020 [cited by applicant]
US 20200377499A1 · Griffin et al. · 2020 [cited by applicant]
US 20200377506A1 · Reddy et al. · 2020 [cited by applicant]
US 20200377507A1 · Griffin et al. · 2020 [cited by applicant]
US 20210087197A1 · Griffin et al. · 2021 [cited by applicant]
US 20210163488A1 · Griffin et al. · 2021 [cited by applicant]
US 20210171530A1 · Reddy et al. · 2021 [cited by applicant]
US 20210188839A1 · Reddy et al. · 2021 [cited by applicant]
US 20210188852A1 · Reddy et al. · 2021 [cited by applicant]
US 20210355118A1 · Reddy et al. · 2021 [cited by applicant]
US 20210403476A1 · Reddy et al. · 2021 [cited by applicant]
US 20220024930A1 · Griffin et al. · 2022 [cited by applicant]
US 20220220118A1 · Griffin et al. · 2022 [cited by applicant]
US 20230322790A1 · Reddy et al. · 2023 [cited by applicant]
US 20240132501A1 · Griffin et al. · 2024 [cited by applicant]
CA 1080712A · 1980 [cited by applicant]
CN 102725290A · 2012 [cited by applicant]
EA 201290121A1 · 2012 [cited by applicant]
EA 201991306A1 · 2020 [cited by applicant]
EP 2818471A1 · 2014 [cited by applicant]
JP S5340798A · 1978 [cited by applicant]
JP 11503437A · 1999 [cited by applicant]
JP 2017001991A1 · 2017 [cited by applicant]
JP 7495962B2 · 2024 [cited by applicant]
TW 201116528A · 2011 [cited by applicant]
WO 2006061428A2 · 2006 [cited by applicant]
WO 2007075567A1 · 2007 [cited by applicant]
WO 2008008539A2 · 2008 [cited by applicant]
WO 2010053757A1 · 2010 [cited by applicant]
WO 2010056865A1 · 2010 [cited by applicant]
WO 2010074807A1 · 2010 [cited by applicant]
WO 2011014462A1 · 2011 [cited by applicant]
WO 2011056985A2 · 2011 [cited by applicant]
WO 2012003392A1 · 2012 [cited by applicant]
WO 2012065546A1 · 2012 [cited by applicant]
WO 2012154760A1 · 2012 [cited by applicant]
WO 2013006463A1 · 2013 [cited by applicant]
WO 2013043925A1 · 2013 [cited by applicant]
WO 2014179492A1 · 2014 [cited by applicant]
WO 2015095370A1 · 2015 [cited by applicant]
WO 2015158283A1 · 2015 [cited by applicant]
WO 2015194670A1 · 2015 [cited by applicant]
WO 2015197567A1 · 2015 [cited by applicant]
WO 2018067786A1 · 2018 [cited by applicant]
WO 2018098491A1 · 2018 [cited by applicant]
WO 2018098499A1 · 2018 [cited by applicant]
WO 2018098500A1 · 2018 [cited by applicant]
WO 2018148745A1 · 2018 [cited by applicant]
WO 2018187480A1 · 2018 [cited by applicant]
WO 2019035951A1 · 2019 [cited by applicant]
WO 2019232209A1 · 2019 [cited by applicant]
WO 2020069322A1 · 2020 [cited by applicant]
WO 2021108513A1 · 2021 [cited by applicant]
WO 2021108625A1 · 2021 [cited by applicant]
US 8,754,103 B2, 06/2014, Corkey et al. (withdrawn) [cited by applicant]
Young, Lee (Authorized Officer), International Search Report and Written Opinion issued Apr. 6, 2021 in corresponding International Application No. PCT/US2020/062317, 14 pages. [cited by applicant]
Flynn et al. “Correlation and Prediction of Mass Transport across Membranes I: Influence of Alkyl Chain Length on Flux-Determining Properties of Barrier and Diffusant”, Journal of Pharmaceutical Sciences. 1972. vol. 61(… [cited by applicant]
Kahlig et al., The novel persistent sodium current inhibitor PRAX-562 has potent anticonvulsant activity with improved protective index relative to standard of care sodium channel blockers. Epilepsia. Mar. 2022;63(3):69… [cited by applicant]
Kolobov et al., Development of a method for the synthesis of compounds of the series 5-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)benzene-1,3-diamine. Khimicheskaya Tekhnologiya. Jan. 2010;11(9):522-524. [cited by applicant]
Wang et al., Multiple Nav1.5 isoforms are functionally expressed in the brain and present distinct expression patterns compared with cardiac Nav1.5. Mol Med Rep. Jul. 2017;16(1):719-729. [cited by applicant]
Chinese Office Action for Application No. 201980047216.4, dated Sep. 24, 2024, 9 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2023/019652, dated Sep. 21, 2023, 10 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2023/019659, dated Sep. 28, 2023, 10 pages. [cited by applicant]
U.S. Appl. No. 16/464,468, filed May 28, 2019, U.S. Pat. No. 1,629,146. [cited by applicant]
U.S. Appl. No. 18/119,963, filed Mar. 10, 2023, 2023-0322790. [cited by applicant]
U.S. Appl. No. 17/058,187, filed Nov. 24, 2020, U.S. Pat. No. 11,866,439. [cited by applicant]
U.S. Appl. No. 17/280,485, filed Mar. 26, 2021, 2021-0403476. [cited by applicant]
U.S. Appl. No. 17/102,586, filed Nov. 24, 2020, U.S. Pat. No. 11,014,931. [cited by applicant]
U.S. Appl. No. 17/214,343, filed Mar. 26, 2021, U.S. Pat. No. 11,731,976. [cited by applicant]
U.S. Appl. No. 17/025,018, filed Mar. 23, 2022, U.S. Pat. No. 11,731,978. [cited by applicant]
U.S. Appl. No. 18/236,156, filed Aug. 21, 2023, 2024-0132501. [cited by applicant]
U.S. Appl. No. 18/860,376, filed Oct. 25, 2024. [cited by applicant]
U.S. Appl. No. 18/927,451, filed Oct. 25, 2024. [cited by applicant]
U.S. Appl. No. 18/860,406, filed Oct. 25, 2024. [cited by applicant]
De Lera Ruiz et al., Voltage-Gated Sodium Channels: Structure, Function, Pharmacology, and Clinical Indications. J Med Chem. Sep. 24, 2015;58(18):7093-118. [cited by applicant]
European Office Action for Application No. 19810530.6, dated Jan. 31, 2022, 9 pages. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2017/063533, dated Jun. 6, 2019, 8 pages. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2019/034653, dated Dec. 10, 2020, 8 pages. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2019/053467, dated Apr. 8, 2021, 7 pages. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2020/062179, dated Jun. 9, 2022, 6 pages. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/Us2020/062317, dated Jun. 9, 2022, 12 pages. [cited by applicant]
Written Opinion of the International Searching Authority and International Search Report for PCT/US2017/063533 mailed Mar. 29, 2019 (10 pages). [cited by applicant]
Written Opinion of the International Searching Authority and International Search Report for PCT/US2017/063534 mailed Mar. 28, 2019 (11 pages). [cited by applicant]
Written Opinion of the International Searching Authority and International Search Report for PCT/US2018/00224 mailed Nov. 5, 2018 (8 pages). [cited by applicant]
Written Opinion of the International Searching Authority and International Search Report for PCT/US2018/018044 mailed May 24, 2018 (10 pages). [cited by applicant]
Written Opinion of the International Searching Authority and International Search Report for PCT/US2018/026099 mailed Aug. 10, 2018 (9 pages). [cited by applicant]
Written Opinion of the International Searching Authority and International Search Report for PCT/US2019/053467 mailed Jan. 14, 2020 (9 pages). [cited by applicant]
Zablocki et al. “Discovery of Dihydrobenzoxazepinone (GS-6615) Late Sodium Current Inhibitor (Late INai), a Phase II Agent with Demonstrated Preclinical Anti-Ischemic and Antiarrhythmic Properties,” Journal of Medicinal… [cited by applicant]
Zaza et al., (2008). “Pathophysiology and pharmacology of the cardiac ‘late sodium current’,” Pharmacology & Therapeutics, 119(3):326-339. [cited by applicant]
Final Office Action received for U.S. Appl. No. 16/638,725 mailed on Apr. 2, 2021, 8 pages. [cited by applicant]
International Preliminary Report on Patentability for International Patent Application No. PCT/US2018/018044 filed on Feb. 13, 2018, 7 pages. [cited by applicant]
International Preliminary Report on Patentability for International Patent Application No. PCT/US2018/026099 filed on Apr. 4, 2018, 6 pages. [cited by applicant]
International Preliminary Report on Patentability for International Patent Application No. PCT/US2017/063507 filed on Nov. 28, 2017, 6 pages. [cited by applicant]
International Preliminary Report on Patentability for International Patent Application No. PCT/US2017/063534 filed on Nov. 28, 2017, 8 pages. [cited by applicant]
International Preliminary Report on Patentability for International Patent Application No. PCT/US2018/000224 filed on Aug. 15, 2018, 6 pages. [cited by applicant]
International Search Report and Written Opinion mailed on Feb. 25, 2021, for PCT Application No. PCT/US2020/062179 filed on Nov. 25, 2020, 7 pages. [cited by applicant]
International Search Report and Written Opinion received for International Patent Application No. PCT/US2020/062317 mailed on Apr. 6, 2021, 14 pages. [cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 16/638,725 mailed on Dec. 11, 2020, 16 pages. [cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 16/887,906 mailed on Jun. 10, 2021, 18 pages. [cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 16/464,483 mailed on Jun. 30, 2021, 22 pages. [cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 16/485,581 mailed on Mar. 10, 2021, 8 pages. [cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 17/102,586 mailed on Jan. 26, 2021, 14 pages. [cited by applicant]
Written Opinion of the International Searching Authority and International Search Report for PCT/US2019/034653 mailed Aug. 9, 2019 (9 pages). [cited by applicant]
File Registry On STN, RN 1347643-11-1, Entered STN: Dec. 2, 2011. [cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 16/500,795 mailed on Apr. 13, 2022, 18 pages. [cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 16/885,605 mailed on Jan. 28, 2022, 10 pages. [cited by applicant]
Restriction Requirement received for U.S. Appl. No. 16/500,795 mailed on Dec. 16, 2021, 12 pages. [cited by applicant]
European Communication to Rule 62 EPC issued in European Patent Application No. 19810530.6 dated Jan. 31, 2022 (9 pages). [cited by applicant]
European Communication to Rules 70(2) and 70a(2) EPC issued in European Patent Application No. 19810530.6 dated Feb. 17, 2022 (1 page). [cited by applicant]
Thakur (Controller), Indian First Examination Report issued in Indian Patent Application No. 202017056206 dated Jun. 14, 2022, with English language translation (7 pages). [cited by applicant]
Chinese Office Action issued in Chinese Patent Application No. 201780084790.8 dated Mar. 9, 2022, with English language translation (23 pages). [cited by applicant]
Japanese Notice of Reasons for Refusal issued in Japanese Patent Application No. 2019-548536 dated Oct. 21, 2021, with English language translation (8 pages). [cited by applicant]
Eurasian Office Action issued in Eurasian Patent Application No. 201991306 dated Aug. 24, 2021, with English language translation (6 pages). [cited by applicant]
Eurasian Office Action issued in Eurasian Patent Application No. 201991306 dated Feb. 25, 2021, with English language translation (8 pages). [cited by applicant]
Eurasian Office Action issued in Eurasian Patent Application No. 202092908 dated Feb. 21, 2022, with English language translation (7 pages). [cited by applicant]
Wei, Chen (Authorized Officer), Singapore Search Report and Written Opinion issued in Singapore Patent Application No. 11202011879R dated May 6, 2022, (10 pages). [cited by applicant]
Koltun, D. O. et al., “Discovery of triazolopyridinone GS 462808, a late sodium current inhibitor (Late INai) of the cardiac NaV 1.5 channel with improved efficacy and potency relative to ranolazine”. Bioorganic & Medic… [cited by applicant]
Albright et al. “Synthesis and anxiolytic activity of 6-(substituted-phenyl)-1,2,4-triazolo[4,3-b]pyridazines,” J. Med. Chem. (1981) vol. 24, pp. 592-600. [cited by applicant]
Anderson et al. “Unexpected efficacy of a novel sodium channel modulator in Dravet Syndrome,” Scientific Reports. 2017. [cited by applicant]
Anderson et al., “Antiepileptic activity of preferential inhibitors of persistent sodium current,” Epilepsia (2014), 55(8), 1274-1283. [cited by applicant]
Baker et al. “The novel sodium channel modulator GS-458967 (GS967) is an effective treatment in a mouse model of SCN8A encephalopathy,” Epilepsia, 2018, 1166-1176. [cited by applicant]
Barbieri et al. “Lale sodium current blocker GS967 inhibits persistent currents induced by familial hemiplegic migraine type 3 mutations of the SCN1 A gene,” The Journal of Headache and Pain (2019) vol. 20, No. 107, pp.… [cited by applicant]
Belardinelli et al. “A Novel, Potent, and Selective Inhibitor of Cardiac Late Sodium Current Suppresses Experimental Arrhythmias,” J. Pharmacol. Exp. Ther. (2013) vol. 344, pp. 23-32. [cited by applicant]
Berge et al., (1977). Pharmaceutical salts, J. Pharmaceutical Sciences, 66(1):1-19. [cited by applicant]
Burbano et al., (2018). “Characterization of a Novel Knock-in Mouse Model of KCNT1 Epileptic Encephalopathy (P2.273),” Neurology, 90(15 Supplement), 2 pages. Abstract Only. [cited by applicant]
Cannon, J. G., (1995). “Chapter Nineteen: Analog Design,” Burger's Medicinal Chemistry and Drug Discovery, Fifth Edition, vol. I: Principles and Practice, Wiley-Interscience, pp. 783-802. [cited by applicant]
Chaplan et al., (1994). “Quantitative assessment of tactile allodynia in the rat paw,” J Neurosci Meth., 53:55-63. [cited by applicant]
Dorwald, F. Z., (2005). “Side Reactions in Organic Synthesis,” Wiley: VCH, Weinheim, 37 pages. [cited by applicant]
Fukaya et al., (2013). “Identification of a Novel Benzoxazolone Derivative as a Selective, Orally Active 18 kDa Translocator Protein (TSPO) Ligand,” J. of Med. Chem., 56(20): 8191-8195. [cited by applicant]
Guan et al. “Synthesis and anticonvulsant activity of a new 6-alkoxy-[1,2,4]-triazolo[4,3-b]pyridazine,” Eur. J. Med. Chem. (2010) vol. 45, pp. 1746-1752. [cited by applicant]
Hackam et al., (2006). “Translation of research evidence from animals to humans,” JAMA, 296(14):1731-1732. [cited by applicant]
Jordan et al., (2003). “Tamoxifen: a most unlikely pioneering medicine,” Nat Rev Drug Discov., 2(3):205-213. [cited by applicant]
Kearney et al., (2001 ). “A gain-of-function mutation in the sodium channel gene Scn2a results in seizures and behavioral abnormalities,” Neuroscience, 702(2):307-317. Abstract Only. [cited by applicant]
Kim et al., (1992). “An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat,” Pain, 50:355-363. [cited by applicant]
Li et al., (2018). “Antisense oligonucleotide therapy for SCN2A gain-of-function epilepsies,” American Epilepsy Society, 28 pages. [cited by applicant]
Patel et al., (2019). “Neuropathy following spinal nerve injury shares features with the irritable nociceptor phenotype: A back-translational study of oxcarbazepine,” Eur J Pain, 23:183-197. [cited by applicant]
Petrou et al., (2018). “Abstract: Antisense oligonucleotide therapy for SCN2A gain-of-function epilepsies,” American Epilepsy Society, available online at <https://www.aesnet.org/abstractslisting/antisense-oligonucleoti… [cited by applicant]
PUBCHEM-CID 58763997 Create Date: Aug. 19, 2012 (14 pages). [cited by applicant]
PUBCHEM-CID 597467 Create Date: Mar. 27, 2005 (15 pages). [cited by applicant]
PUBCHEM-CID 82381512 Create Date: Oct. 20, 2014 (10 pages). [cited by applicant]
PUBCHEM-CID 89077556 Create Date: Feb. 13, 2015 (11 pages). [cited by applicant]
STN Chemical Structure Search Results dated Apr. 14, 2019 (36 pages). [cited by applicant]
STN Chemical Structure Search Results dated Apr. 2018 (55 pages). [cited by applicant]
STN Chemical Structure Search Results dated Apr. 23, 2019 (45 pages). [cited by applicant]
STN Chemical Structure Search Results dated Feb. 2018 (29 pages). [cited by applicant]
STN Chemical Structure Search Results dated Jan. 15, 2020 (22 pages). [cited by applicant]
STN Chemical Structure Search Results dated Jan. 2018 (23 pages). [cited by applicant]
STN Chemical Structure Search Results dated Mar. 20, 2018 (264 pages). [cited by applicant]
STN Chemical Structure Search Results dated Mar. 20, 2018 (83 pages). [cited by applicant]
BTN Chemical Structure Search Results dated Mar. 6, 2017 (480 pages). [cited by applicant]
STN Chemical Structure Search Results dated Mar. 6, 2017 (511 pages). [cited by applicant]
STN Chemical Structure Search Results dated May 18, 2016 (102 pages). [cited by applicant]
STN Chemical Structure Search Results dated Nov. 1, 2017 (107 pages). [cited by applicant]
STN Chemical Structure Search Results dated Nov. 21, 2017 (85 pages). [cited by applicant]
STN Chemical Structure Search Results dated Nov. 3, 2017 (57 pages). [cited by applicant]
STN Chemical Structure Search Results dated Nov. 6, 2017 (123 pages). [cited by applicant]
STN Chemical Structure Search Results dated Nov. 6, 2017 (7 pages). [cited by applicant]
Venkatesh et al., (2000). “Role of the development scientist in compound lead selection and optimization,” J Pharm Sci., 89(2):145-54. [cited by applicant]
Wagnon et al., (2015). “Convulsive seizures and SUDEP in a mouse model of SCN8A epileptic encephalopathy,” Human Molecular Genetics, 24(2):506-515. [cited by applicant]
Wilen et al., (1977). “Strategies in optical resolutions,” Tetrahedron, 33(21 ):2725-2736. [cited by applicant]
Woodland et al., (2015). “Discovery of Inhibitors of Trypanosoma brucei by Phenotypic Screening of a Focused Protein Kinase Library,” ChemMedChem, 10(11 ): 1809-1820. [cited by applicant]
Wengert et al. “Prax330 reduces persistent and resurgent sodium channel currents and neuronal hyperexcitability of subiculum neurons in a mouse model of SCN8A epileptic encephalopathy,” Neuropharmacology (2019) vol. 158… [cited by applicant]
Written Opinion of the International Searching Authority and International Search Report for PCT/US2017/063507 mailed Mar. 29, 2019 (9 pages). [cited by applicant]